Molecular imaging is providing key data to inform drug development. It furthers understanding of the basic mechanisms underlying the biology of cancer and illustrates drug distribution patterns. Such knowledge is fundamental to assessments of the pharmacology, pharmacokinetics, safety, drug–drug interactions, transport and metabolism of therapeutic agents.
PET and MRI are valuable tools for tumor surveillance and evaluation of metastatic potential and treatment effects in a variety of preclinical models. 3D tomographic imaging and quantification of radiotracers have been particularly useful in evaluating candidate small-molecule oncology tracers and following the in vivo biodistribution and targeting of novel therapeutic compounds.
The Bruker BioSpec range provides high-resolution MRI enabling the effects of novel anti-tumor treatments to be evaluated at systemic, organ, tissue, and even molecular level. Bruker's molecular drug imaging system, SolariX XR FTMS, facilitates the localization of multi-generational metabolic products of drug candidates and automatically generates images of downstream metabolites.
Bruker’s commitment to provide customers with unparalleled help throughout the buying cycle, from initial inquiry to evaluation, installation, and the lifetime of the instrument is now characterized by the LabScape service concept.
LabScape Maintenance Agreements, On-Site On-Demand and Enhance Your Lab are designed to offer a new approach to maintenance and service for the modern laboratory